Segall Bryant & Hamill LLC Sells 2,947 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Segall Bryant & Hamill LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 3.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,451 shares of the biopharmaceutical company’s stock after selling 2,947 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Cytokinetics were worth $3,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in CYTK. Darwin Global Management Ltd. bought a new stake in shares of Cytokinetics during the 2nd quarter valued at $246,074,000. Integral Health Asset Management LLC grew its holdings in Cytokinetics by 122.2% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $54,180,000 after buying an additional 550,000 shares in the last quarter. Hood River Capital Management LLC increased its position in shares of Cytokinetics by 5.9% during the second quarter. Hood River Capital Management LLC now owns 737,637 shares of the biopharmaceutical company’s stock valued at $39,965,000 after buying an additional 40,990 shares during the period. Great Point Partners LLC lifted its holdings in shares of Cytokinetics by 134.5% in the second quarter. Great Point Partners LLC now owns 474,202 shares of the biopharmaceutical company’s stock worth $25,692,000 after buying an additional 272,000 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Cytokinetics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 470,967 shares of the biopharmaceutical company’s stock valued at $25,517,000 after acquiring an additional 105,000 shares during the period.

Analysts Set New Price Targets

CYTK has been the topic of a number of analyst reports. Mizuho upped their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Wednesday, September 4th. Royal Bank of Canada initiated coverage on Cytokinetics in a research report on Friday, November 8th. They set an “outperform” rating and a $80.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.93.

Insiders Place Their Bets

In other news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $50.55, for a total transaction of $252,750.00. Following the completion of the transaction, the chief executive officer now directly owns 397,456 shares in the company, valued at $20,091,400.80. This trade represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 7,384 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $57.01, for a total transaction of $420,961.84. Following the sale, the executive vice president now directly owns 122,920 shares in the company, valued at $7,007,669.20. This trade represents a 5.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,078 shares of company stock valued at $3,514,119 in the last quarter. Insiders own 3.40% of the company’s stock.

Cytokinetics Trading Up 3.0 %

NASDAQ CYTK opened at $49.10 on Friday. The firm has a market cap of $5.79 billion, a PE ratio of -9.13 and a beta of 0.78. Cytokinetics, Incorporated has a 1-year low of $30.68 and a 1-year high of $110.25. The stock has a 50-day moving average of $53.60 and a 200-day moving average of $54.81. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $1.21 million. During the same period in the previous year, the business posted ($1.35) earnings per share. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.31 EPS for the current year.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.